About US
Contact us
-
Mereo BioPharma’s BPS-804 drug accepted for participation in EMA’s adaptive pathways programmeUK-based biopharmaceutical company Mereo BioPharma has announced that its BPS-804 drug has been accepted to participate in the European Medicines Agency’s (EMA) adaptive pathways programme. As part o2017/2/22
-
Amygdala Neurosciences to acquire GS-6637 from Gilead SciencesUS-based Amygdala Neurosciences has signed an agreement to acquire GS-6637, a ALDH2 inhibitor from Gilead Sciences. GS-6637 is a Phase II ready compound with the potential to treat behaviour and subs2017/2/21
-
Japan’s Takeda acquires US cancer drug manufacturer ARIAD for $5.2bnJapan-based Takeda Pharmaceutical Company has completed the previously announced acquisition of American oncology company ARIAD Pharmaceuticals for $5.2bn. The acquisition was concluded through a ten2017/2/21
-
ALK receives acceptance for ragweed sublingual allergy immunotherapy tabletDanish-based pharmaceutical company ALK’s European regulatory filing for its ragweed sublingual allergy immunotherapy (SLIT) tablet has received acceptance from the relevant health authorities. The f2017/2/20
-
Vedanta, Stanford and Leiden universities partner to study food allergies in childrenUS-based Vedanta Biosciences has collaborated with Stanford University School of Medicine and Leiden University Medical Center to study food allergies in children and patients with C difficile infecti2017/2/20
-
Sanofi, Novo and Lilly face class action over 'astounding' insulin price hikesAn “insidious” pricing war has left patients with huge, “devastating” bills for their needed insulins, according to a new class actionlawsuitfiled against Sanofi, Novo Nordisk and Eli Lilly. The plai2017/2/17
-
Mylan faces FTC antitrust probe over generic-thwarting EpiPen tweaksMylan’s EpiPen saga isn’t over. After a series of Congressionaldemandsand hearings, back-and-forth with government officials, and a tentative settlement with the Justice Department over Medicaid overc2017/2/17
-
AZ nabs 6 more months of Symbicort exclusivity—and the sales that come with itAstraZeneca’s aging respiratory giant Symbicort won a coveted pediatric exclusivity nod from the FDA on Wednesday, giving the brand a longer life—and potentially hundreds of millions in additional sal2017/2/16
-
Teva faces billions in lost sales as court tosses four long-acting Copaxone patentsIt’s déjà vu for Teva Pharmaceutical in a bad, bad way. Late Monday, the Israeli drugmakerconfirmedthat the U.S. District Court for the District of Delaware had upturned four of its patents on the lo2017/2/16
-
Inherited pay-for-delay penalties are getting expensive for 'cash-strapped' TevaTeva is eager to start moving in the right direction after a particularly rocky 2016. Problem is, it’s still paying for pay-for-delay decisions made by its products’ previous owners. Both Paul Bisaro2017/2/15